
MHRA Recalls Novartis Cough and Cold Medicine
Agency issues precautionary recall due to manufacturing fault.
The Medicines and Healthcare products Regulatory Agency (MHRA) issued a recall on certain batches of Novartis Consumer Health UK Ltd’s Tixylix cough and cold medicines because of a possible fault in the manufacturing process of the tamper seal that might result in small pieces of plastic being found in the liquid medicines. MHRA says that there is no evidence, as of yet, of problems occurring as a result of this manufacturing fault but they are recalling the drugs as a precautionary measure.
“This is a precautionary recall and there is currently no evidence that people have had any problems with these medicines,” said Adam Burgess, the MHRA’s Head of Defective Medicines Reporting Centre (DMRC), in
Specific batches of the Tixylix medicines being recalled by Novartis include:
Tixylix Toddler Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Toddler Syrup 150mL (Glycerol)—PL 00030/0150
Tixylix Baby Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Blackcurrant Flavour Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Chesty Cough 100mL (Guaifenesin)—PL 00030/0082
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.